amplifying the complement response and forming the C3b 2 Bb complex that cleaves C5 to initiate the formation of large, membraneinserted lytic pores. In addition, deposition of C3b on target surfaces generates two important cellular responses. C3b and its proteolytic fragments iC3b and C3dg ( Fig. 1 ) are recognized by complement receptors (CR) on phagocytic cells (for example, CR1 (CD35), CR3 (CD11b/CD18), CR4 (CD11c/CD18) 2 and CRIg 9 ) to induce the uptake of opsonized particles, and by CR2 (CD35) to upregulate the B-cell response 10,000-fold through the co-stimulatory and B-cell receptor complexes 10 . The formation of C3b is therefore a crucial step that requires tight regulation. Host cells express several cell-surface and soluble regulators that disrupt the C3bBb complex or aid in the proteolytic degradation of C3b into iC3b and ultimately to C3dg and C3c 11, 12 . Bacteria and viruses use proteins with similar activities to evade the complement response. Because C3b binds many soluble proteins and cell-surface receptors 4 , whereas C3 has few binding partners, the proteolytic activation of C3 into C3b probably induces conformational changes that form the various cryptic binding sites. Conformation-dependent mechanisms are probably common to the homologous proteins of the C3/a2-macroglobulin family, which are an ancient family of host defence proteins.
Here we present the crystal structure of human C3b solved at 4-Å resolution by molecular replacement using the structures of C3, C3c 5 and C3d 13 ; see Methods and Supplementary Table 1 and Supplementary Fig. 1 . C3b is generated from C3 by proteolytic removal of the small anaphylatoxin domain (residues 650-726) to produce a b-chain (residues 1-645) and a shortened a-chain, denoted a9 (residues 727-1,641). The structure of C3b reveals that this conversion is accompanied by marked structural rearrangements that result in differences in atomic position of up to 95 Å (Fig. 1) . The domain rearrangements can be described by a metaphor of a puppeteer with a body formed by the b-ring domains (macroglobulin (MG) 1-6 domains and linker (LNK) domain), shoulders (domains MG7 and MG8), a neck (anchor region), a head (C345C domain) and an arm ('complement C1r/C1s, Uegf, Bmp1' (CUB) domain) with a puppet (thioester-containing domain (TED)). In C3 the puppet (TED domain) is embraced by the arm (CUB) and held against the shoulder (MG8). In C3b the shoulders (MG7 and MG8), neck (anchor) and head (C345C) have twisted, the arm (CUB) has extended downwards and the puppet (TED) has dropped (see Supplementary Table 2 and Movie 1). In its new position, the TED domain contacts MG1 of the b-ring. The single amino-acid residue difference, Arg80Gly in MG1, that is responsible for the C3S/C3F phenotype difference 14 is located in the MG1-TED interface. The overall arrangement of the core domains (MG1-8, LNK, anchor and C345C) resembles more the structural arrangement of the final proteolytic, downregulated fragment C3c than the native C3 molecule. This includes the relocation of the a9 amino-terminal segment (a9NT) and the conformational transition of the MG8 bab-motif in C3 to a baa-motif in C3b and C3c. The TED domain (which is absent in C3c) takes on the conformation that is seen in the C3d fragment 13 . Thus, in the proteolytic conversion of C3 to C3b, iC3b and finally C3c and C3dg, the main conformational rearrangements occur upon the first activation step that converts the native, resting C3 into the active C3b.
Surface attachment of C3b requires exposure and activation of the thioester moiety, Cys 988-Gln 991 of the TED domain. In the structure of C3b these residues are completely exposed to the solvent, whereas in C3 they are hidden 5 85 Å away from the site of exposure. In addition, the TED domain in C3b has changed its conformation from C3-like 5 to C3d-like 13 , where the arrangement of the reactive residues corresponds to the formation of the acyl-imidazole intermediate, which is highly reactive towards hydroxyl nucleophiles 5, 15 ( Fig. 2a) . The overall domain rearrangements might be coupled to the conformational changes in the TED domain by a pulling force that stretches the N-terminal segment (helices a0 and a1) preceding the thioester cysteine. Surface-charge calculation shows a single, strong electro-positive patch near the thioester, on a protein that is otherwise mostly and strongly electro-negative (Fig. 2b) . Putatively, the electropositive patch on the TED domain is involved in orienting the molecule with respect to negatively charged target surfaces, such as bacterial cells or apoptotic host cells. This orientation results in a footprint of 50 3 90 Å 2 formed by the TED, MG1, MG4 and MG5 domains, which is in remarkable agreement with the figure of ,4,750 Å 2 that was estimated from fully covered erythrocytes 16 . Proper orientation of the TED domain close to the target surface might be important for the highly reactive and short-lived (t K , 100 ms) 17 acyl-imidazole intermediate to react covalently with the target surface instead of the surrounding solvent.
Conversion of C3 to C3b exposes binding sites for proteins involved in convertase formation (factor B and properdin) and dissociation (regulators of complement). We analysed the C3b surface for exposure of previously hidden interfaces and for new arrangements of sites already exposed on C3 (Fig. 3a, b) . The new N-terminal segment a9NT (residues 727-745) carries four acidic residues that are important for binding factor B. Previously we have shown that this segment undergoes a drastic relocation between the native C3 and the final proteolytic fragment C3c (ref. 5). The structure of C3b reveals that this relocation, in which the a9NT moves through the central hole of the b-ring and becomes exposed on the opposite side of the molecule, occurs during the activation of C3 into C3b. Mapping other putative binding sites for factor B onto the C3b surface (Fig. 3c) gives three exposed sub-sites, a9NT
18 , strand b4 of CUB 19 and C345C 20 (whereas the putative 'complement C2 receptor inhibitor trispanning' (CRIT) like site 21 remains mostly occluded), that are located around the shoulder (MG7), neck and head region. This region undergoes significant structural rearrangements from C3 to C3b (Fig. 2b) . The absence of novel features on the surface of the b-ring excludes this region as a primary binding site of factor B. In addition, the TED domain is probably not a primary binding site for factor B, because cobra-venom factor, which is a C3b homologue that can make potent fluid-phase convertases, lacks a TED domain.
The association of C3b and factor B is accelerated by properdin, which also stabilizes the resulting convertase C3bBb. The putative binding site of properdin has been mapped to residues 1402-1435 (ref. 22) , which form the structurally variable bab-baa motif in the MG8 domain. This site is hidden in C3 and becomes exposed in C3b (Fig. 3a) . Thus, the arrangement of putative binding sites identifies the arm-shoulder-neck-head region as being responsible for binding factor B and properdin. Regulators of complement (including soluble factor H and cell-surface CR1 and decay-accelerating factor (DAF/CD55)) dissociate the C3bBb complex and act as co-factors in the proteolysis of C3b into iC3b (for example, factor H, CR1 and cell-surface membrane-cofactor protein (MCP/CD46)). Three regions have been implicated in regulator binding: the a9NT (for factor H and CR1), the MG6 domain (for factor H and CR1) 23 and the TED domain (for factor H) 24 . In the structure of C3b, a9NT and MG6 form one continuous exposed region, indicating that the binding site for factor B overlaps with that for factor H and CR1. Therefore, dissociation of C3bBb by these regulators is achieved through steric hindrance. Binding of factor H to the TED domain might be linked to its cofactor activity. Protease factor I, which degrades C3b by three sequential cleavages (see Supplementary Fig.  2 ), requires these cofactors (for example, factor H, CR1 or MCP), putatively for orienting its protease domain and unraveling the CUB domain. The resulting iC3b no longer binds factor B. As the arrangement of the 10 domains in C3c is similar to that in C3b, it is likely that iC3b has the same overall core-domain arrangement. Therefore, it seems that the stability of the convertase depends on the structure and orientation of the CUB domain with respect to the rest of C3b.
C3b, iC3b and C3dg induce various cellular responses. C3b and iC3b act as opsonins to facilitate the uptake of tagged particles. This occurs through specific recognition of C3b and iC3b by complement receptors on various phagocytic cells 2 . C3b is recognized by CR1 and CRIg 9 whereas iC3b is also recognized by the integrins CR3 and CR4. Furthermore, pathogen-bound iC3b and C3dg, but not C3b, contribute to an increased antibody response by binding to CR2 on B cells. A putative binding site for CR2 has been mapped partly on the interface between the TED and MG1 domains 25 , close to the TED-CUB connections. Therefore it seems likely that, when the TED-CUB connections in iC3b are disrupted, the TED-MG1 interface is opened to provide a new interface for binding CR2 on B cells. Dislodging the iC3b core from the TED domain and the target surface might provide the new signal for binding the integrins CR3 and CR4 on phagocytic cells.
In summary, these data indicate a conformational pathway for C3 and its fragments (Fig. 4) that determines their biological activity. In this pathway, the b-ring provides a stable platform for the functionally important domains of the a-chain that undergo conformational rearrangements. We expect that similar rearrangements occur in homologous host-defence proteins (see Supplementary Fig. 3 , where we modelled native a2-macroglobulin and activated a2-macroglobulin in electron-microscopy reconstruction maps). Insights into these marked conformational changes are essential for understanding convertase activity and regulation, and will help in the development of complement inhibitors for therapeutic use.
METHODS
Protein purification. C3 was isolated from citrated human plasma as previously described 26 with the exception that after the diethylaminoethyl (DEAE) column it was converted to C3b by limited digestion with trypsin for 2 min at 37 uC with 1% w/w enzyme/substrate (the reaction was stopped by the addition of 3% w/w soybean trypsin inhibitor). The C3b was purified immediately by gel filtration over a Superdex 200 size-exclusion column in phosphate buffered saline pH 7.4, followed by anion-exchange chromatography over a Mono-Q column (equilibrated in 50 mM phosphate buffer, pH 7.5 and eluted with 20 column volumes of 0-500 mM NaCl gradient). The protein was then treated with 100 mM iodoacetamide (30 min at 4 uC) to prevent dimerization of the C3b by the free cysteine, concentrated and further purified over a Mono-S column equilibrated in 50 mM phosphate buffer pH 6.0 and eluted with 20 column volumes of 0-500 mM NaCl gradient. The C3b was concentrated to 10 mg ml -1 , dialysed against 10 mM Tris pH 7.4 and frozen at -70 uC until crystallization. Crystallization and crystallography. C3b was crystallized in sitting drops from mother liquor containing 9% w/v PEG-monomethylether 2000, 100 mM sodium acetate, 10 mM taurine and 50 mM Bis-Tris propane pH 7.8 at 30 uC. Crystals grew to 100 3 100 3 60 mm within 2 weeks. For cryo-protection, the well solution was replaced by mother liquor with increased (to 40% w/v) PEG-monometylether 2000 and equilibrated for 24 h at 30 uC; and crystals were flash-cooled in liquid nitrogen. Crystals displayed space group P2 1 2 1 2 (a 5 123.9, b 5 128.5, c 5 147.0 Å ), contained one molecule per asymmetric unit and diffracted to 4-Å resolution at ESRF beamline ID14-EH4. Diffraction data was processed using MOSFLM/CCP4 (ref. 27) (data statistics are presented in Supplementary  Table 1) . Structure determination. C3b was solved by molecular replacement with Phaser 28 . First, the MG1-MG6 and LNK domains of C3c (pdb code 2A74) 5 were placed. Second, we placed C3d (pdb code 1C3D) 13 , yielding a large log-likelihood gain (see Supplementary Table 1B) as compared with a loss of log-likelihood when testing the TED domain from C3 (pdb code 2A73) 5 . Finally, we added stepby-step MG8, MG7, a9NT, anchor and C345C from C3c and CUB from C3, respectively, using molecular graphics in Coot 29 with rigid-body refinement in Phaser. This yielded a 97% complete model that was completed by model building of the CUB-TED connections (17 residues) and slight adjustments in the other domain-domain connections. Owing to limited resolution only one round of restrained refinement followed by one round of 'translation, liberation and screw-rotation' (TLS) refinement (with individual B-factors set to 50 Å 2 ) were performed in REFMAC 27 . The final refined model of C3b, consisting of 1,531 residues, had R and R free values of 27.3 and 32.3%, respectively (for model statistics see Supplementary Table 1) . Electron density for each domain is shown in Supplementary Fig. 1; see also Fig. 1b . The central domains fitted excellently in the electron density; the outermost domains (CUB, TED and C345C) showed Fig. 2 ). These conformational changes determine the binding affinities towards soluble proteins (for example, factor B, properdin and factor H) and cell-surface receptors (for example, CR1-4, CRIg, DAF and MCP) that underlie the biological activity.
